U.S. Non-Invasive Aesthetic Treatment Market (By Procedure: Injectable, Skin Rejuvenation, Others; By End Use: Hospitals & Surgery Centers, Medical Spa, Traditional Spa, HCP Owned Clinic, Others) Regional Outlook and Forecast 2024 to 2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. Non-Invasive Aesthetic Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: U.S Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. Non-Invasive Aesthetic Treatment Market Revenue and Volume, by Procedure, 2024-2033
8.1.1. Injectable
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Skin Rejuvenation
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Others
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1. U.S. Non-Invasive Aesthetic Treatment Market Revenue and Volume, by End-Use, 2024-2033
9.1.1. Hospitals & Surgery Centers
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Medical Spa
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Traditional Spa
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1.4. HCP Owned Clinic
9.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast (2021-2033)
10.1. U.S.
10.1.1. Market Revenue and Volume Forecast, by Procedure (2021-2033)
10.1.2. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.1. Galderma S.A.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Allergen
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. El. En. SpA
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Alma Lasers
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Johnson & Johnson
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Cynosure
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Solta Medical
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Syneron Candela
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Lumenis
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Merz Pharma
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample